Lynk Biotechnologies Pte Ltd   Report issue

For profit Phase 4
Founded: Singapore Singapore (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2016
NCT03743896
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Lynk Biotechnologies Pte Ltd

Active Ingredients

Drugs in Phase 4 Trials (1)

glucosamine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 4)

Osteoarthritis, Knee (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1